VigiPallia : Résultats

THERAPEUTIQUE ANTI CANCEREUSE

0 sélectionnée(s) / 190 réponse(s)

(1) 2 3 4 ... 10 > »

Adverse events in deceased hospitalised cancer patients as a measure of quality and safety in end-of-life cancer care

HAUKLAND, Ellinor Christin ; VON PLESSEN, Christian ; NIEDER, Carsten ; VONEN, Barthold
BMC palliative care, 2020, vol.19, n°1, p. 1-9

Document en ligne

Relatives of deceased patients with metastatic lung cancer’s views on the achievement of treatment goals and the choice to start treatment - a structured telephone interview study

MIERAS, Adinda ; ONWUTEAKA-PHILIPSEN, Bregje D. ; BECKER-COMMISSARIS, Annemarie ; BOS, Jose C. M. ; PASMAN, H. Roeline W.
BMC palliative care, 19/06/2020, vol.19, n°1, p. 1-9

Document en ligne

The impact of initial treatment strategy and survival time on quality of end-of-life care among patients with oesophageal and gastric cancer - a population-based cohort study

DALHAMMAR, Karin ; MALMSTROM, Marlene ; SCHELIN, Maria ; FALKENBACK, Dan ; KRISTENSSON, Jimmie
Plos one, 22/06/2020, vol.15, n°6, p. 1-15

Document en ligne

A randomized, placebo-controlled, double-blind study of mocycline for reducing the symptom burden experienced by patients with advanced pancreatic cancer

KAMAL, Mona ; WANG, Xin Shelley ; SHI, Qiuling ; MENDOZA, Tito ; GARCIA-GONZALEZ, Araceli ; BOKHARI, Raza H. ; CLEELAND, Charles S. ; FOGELMAN, David R.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 05/2020, vol.59, n°5, p. 1052-1058

Document en ligne

Reasons for chemotherapy discontinuation and end-of-life in patients with gastrointestinal cancer - a multicenter prospective AGEO study

PALMIERI, Lola-Jade ; DUBREUIL, Olivier ; BACHET, Jean-Baptiste ; TROUILLOUD, Isabelle ; LOCHER, Christophe ; CORIAT, Romain ; MORYOUSSEF, Frederick ; LANDI, Bruno ; PERKINS, Géraldine ; HAUTEFEUILLE, Vincent ; DOAT, Solène
Clinics and research in hepatology and gastroenterology, 11/05/2020, p. 1-8

Document en ligne

Palliative care in the context of immune and targeted therapies - a qualitative study of bereaved carers' experiences in metastatic melanoma

FOX, Jennifer A. ; ROSENBERG, John ; EKBERG, Stuart ; LANGBECKER, Danette
PALLIATIVE MEDICINE, 27/04/2020, Pagination inconnue

Document en ligne

Palliative radiotherapy for oncologic emergencies in the setting of Covid-19 - approaches to balancing risks and benefits

YERRAMILLI, Divya ; XU, Amy J. ; GILLESPIE, Erin F. ; SHEPHERD, Annemarie F. ; BEAL, Kathryn ; GOMEZ, Daniel ; YAMADA, Josh ; TSAI, C. Jillian ; YANG, T. Jonathan
Advances in radiation oncology, 08/04/2020, p. 1-6

Document en ligne

Survival after anticancer treatment of terminally ill patients with ovarian carcinoma

KAJIYAMA, Hiroaki ; SUZUKI, Shiro ; SHIMBO, Akiko ; UTSUMI, Fumi ; YOSHIKAWA, Nobuhisa ; KIKKAWA, Fumitaka
JOURNAL OF PALLIATIVE MEDICINE, 15/04/2020, Pagination inconnue

Document en ligne

Comment maman a tué le chef des pamplemousses

BOUGEAULT, Pascale
Rue de l'échiquier jeunesse , 2018 , 40 p.

ABRAVAN, Azadeh ; EIDE, Hanne Astrid ; HELLAND, Aslaug ; MALINEN, Eirik
Clinical and translational radiation oncology, 05/2020, vol.22, p. 15-21

Document en ligne

Thème : Médecine. Cote : eD03.02

RADIOTHERAPIE ; CANCER RESPIRATOIRE ; THERAPEUTIQUE ANTI CANCEREUSE ; HEMATOLOGIE

Background: Lymphopenia during radiotherapy (RT) may have an adverse effect on treatment outcome. The aim of this study is to investigate associations between lymphopenia and RT parameters in patients with advanced lung cancer. Moreover, to investigate the prognostic role of lymphopenia, blood protein levels, and treatment and patient-related factors.
Material and Methods: Sixty-two advanced stage non-small cell lung cancer (NSCLC) patients were retrospectively analyzed. Blood counts were available prior to, during, and after RT (3Gyx10). For each patient, a thoracic volume of interest (VOI) -including thoracic soft tissue and trabecular bone- was obtained by applying a CT window of -500 to 1200 HU in the planning CT. Dose parameters from thoracic VOI and other regions including lungs and vertebrae were calculated. Association between risk of lymphopenia = G3 (lymphocytes at nadir according to CTCAE v4.0) and therapeutic parameters was investigated using Logistic regression. Relationships between overall survival (OS) and RT dose parameters, baseline blood counts and protein levels, and clinical factors were evaluated using Log-rank and Cox models.
Result: Mean thoracic RT dose (odds ratio [OR] 1.67; p = 0.04), baseline lymphocytes (OR 0.65; p = 0.01), and corticosteroids use (OR 6.07; p = 0.02) were significantly associated with increased risk of lymphopenia = G3 in multivariable analysis. Worse OS was associated with high mean thoracic RT dose, high CRP/Albumin, large tumor volume and corticosteroids use (p < 0.05, univariate analysis), but not with lymphopenia = G3. CRP/Albumin ratio > 0.12 (hazard ratio [HR] 2.28, p = 0.03) and corticosteroid use (HR 2.52, p = 0.01) were independently associated with worse OS.
Conclusion: High thoracic RT dose gave a higher risk of lymphopenia = G3; hence limiting dose volume to the thorax may be valuable in preventing severe lymphopenia for patients receiving palliative fractionated RT. Still, lymphopenia = G3 was not associated with worse OS. however, high baseline CRP/Albumin was associated with poorer OS and may carry important information as a prognostic factor of OS in advanced NSCLC receiving palliative RT.

Origine : PubMed

A targeted needs assessment to improve referral patterns for palliative radiation therapy

PARKER, Sean M. ; WEI, Randy L. ; JONES, Joshua A. ; MATTES, Malcolm D.
Annals of palliative medicine, 09/2019, vol.8, n°4, p. 516-522

Document en ligne

Concurrent hospice care and cancer-directed treatment for advanced lung cancer and receipt of aggressive care at the end of life in the Veteran's Health Administration

PRESLEY, Carolyn J. ; HAN, Ling ; O'LEARY, John R. ; ZHU, Weiwei ; CORNEAU, Emily ; CHAO, Herta ; SHAMAS, Tracy ; ROSE, Michal ; LORENZ, Karl A. ; LEVY, Cari R. ; MOR, Vincent ; GROSS, Cary P.
JOURNAL OF PALLIATIVE MEDICINE, 02/03/2020, Pagination inconnue

Document en ligne

Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors

PETRILLO, Laura A. ; EL-JAWAHRI, Areej ; NIPP, Ryan D. ; LICHTENSTEIN, Morgan R. L. ; DURBIN, Sienna M. ; REYNOLDS, Kerry L. ; GREER, Joseph A. ; TEMEL, Jennifer S. ; GAINOR, Justin F.
Cancer, 06/03/2020, Pagination inconnue

Document en ligne

Heterogeneity of first-line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients - a real-world evidence study

DIJKSTERHUIS, Willemieke P. M. ; VERHOEVEN, Rob H. A. ; SLINGERLAND, Marije ; HAJ MOHAMMAD, Nadia ; DE VOS-GEELEN, Judith ; BEEREPOOT, Laurens V. ; VAN VOORTHUIZEN, Theo ; CREEMERS, Geert-Jan ; VAN OIJEN, Martijn G. H. ; VAN LAARHOVEN, Hanneke W. M.
INTERNATIONAL JOURNAL OF CANCER, 01/01/2020, vol.146, n°7, p. 1889-1901

Document en ligne

Comparative studies on the potential use of 177Lu-based radiopharmaceuticals for the palliative therapy of bone metastases

ZAKALY, Hesham M. H. ; MOSTAFA, Mostafa Y. A. ; DERYABINA, Darya ; ZHUKOVSKY, Michael
International journal of radiation biology, 11/02/2020, p. 1-34

Document en ligne

Thème : Médecine.

METASTASE OSSEUSE ; THERAPEUTIQUE ANTI CANCEREUSE ; POSOLOGIE

Purpose: In recent years, radionuclides like 177Lu have been considered promising material for the creation of therapeutic radiopharmaceuticals. With the therapeutic use of radiopharmaceuticals, the absorbed doses per tumor may exceed 10 Gy. It is extremely important that doses absorbed by healthy organs and tissues do not exceed the threshold for the incidence of deterministic effects.
Materials and methods: The potential use of the radionuclide lutetium-177 for the palliative treatment of pain in bone metastases is analyzed. The radionuclide 177Lu is a beta-emitting nuclide with a maximal energy of 0.49 MeV and a half-life of 6.6 days (161 h). Two therapeutic agents were considered: methylene diphosphonate (MDP) and ethylenediamine tetramethylene phosphonic acid (EDTMP). Both drugs contain phosphorus compounds in their composition, which ensures high tropism in bone tissue. For both drugs, biokinetic models of 177Lu’s behavior in the human body are created. A number of studies have shown that the radiochemical stability of these drugs is about 99%: these calculations took into account the presence of a free 177Lu radionuclide in each solution. The absorbed doses in organs and tissues when using the radiopharmaceuticals 177Lu-MDP and 177Lu-EDTMP, as well as the currently used drugs 153Sm-EDTMP and 89SrCl2, are compared. In order to assess the risk of the patient’s exposure to a radiopharmaceutical, the absorbed doses are calculated for each organ where the radioactive label is mainly deposited: the kidneys, red bone marrow, liver and bone surface.
Results: The intensity of dose accumulation when using different drugs on the pathological focus is different. The drug 177Lu-MDP is faster than other drugs when it comes to the full realization of the expected dose; therefore, a therapeutic effect is achieved faster when it is used. The slowest absorbed dose accumulates when strontium chloride is used. To compare the effectiveness of preparations based on the 177Lu radionuclide, an analysis of the radiopharmaceuticals currently used for the palliative therapy of bone metastases (89SrCl2 and 153Sm-EDTMP) was performed. For 89Sr, the most vulnerable organs are the kidneys, red bone marrow and liver, while for 153Sm-EDTMP, red marrow bone is most vulnerable. For radiopharmaceuticals based on the 177Lu radionuclide, the most vulnerable organs are the kidneys, liver and red bone marrow. This proves the effectiveness of the 177Lu-MDP and 177Lu-EDTMP radiopharmaceuticals.
Conclusions: According to the results of the calculations, 177Lu-EDTMP and 177Lu-MDP demonstrate the best results for the palliative therapy of bone metastases.

Origine : PubMed

Successful treatment of unresectable advanced rectal cancer with liver metastases by hemostasis re-irradiation of the rectal cancer and palliative low-dose whole-liver radiation therapy - a case report

YASUDA, Takeshi ; TANAKA, Osamu ; HAYASHI, Sadanari ; NAKAHATA, Yuki ; YASUDA, Yuriko ; OMATSU, Tatsushi ; OBORA, Akihiro ; KOJIMA, Takao ; MATSUO, Masayuki ; YAGI, Nobuaki
Clinical journal of gastroenterology, 02/2020, vol.13, n°1, p. 11-16

Document en ligne

Lenvatinib vs. palliative therapy for stage IVC anaplastic thyroid cancer

IWASAKI, Hiroyuki ; TODA, Soji ; SUGANUMA, Nobuyasu ; MURAYAMA, Daisuke ; NAKAYAMA, Hirotaka ; MASUDO, Katsuhiko
Molecular and clinical oncology, 02/2020, vol.12, n°2, p. 138-143

Document en ligne

Anticancer therapy within the last 30 days of life - results of an audit and re-audit cycle from an Australian regional cancer centre

NGUYEN, Mike ; NG YING KIN, Sean ; SHUM, Evonne ; WANN, Alysson ; TAMJID, Babak ; SAHU, Arvind ; TORRES, Javier
BMC palliative care, 27/01/2020, vol.19, n°1, p. 1-10

Document en ligne

Disparity in oesophageal cancer management in South Africa - a comparison between two tertiary centres with special focus on the palliation of dysphagia

NEL, D. ; OMAR, M. ; CHINNERY, G. ; JONAS, E.
South African journal of surgery, 06/2019, vol.57, n°2, p. 10-15

Anti-epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma

CHEN, Chen ; ZHOU, Yixin ; ZHANG, Xuanye ; FU, Sha ; LIN, Zuan ; FANG, Wenfeng ; YANG, Yunpeng ; HUANG, Yan ; ZHAO, Hongyun ; HONG, Shaodong ; ZHANG, Li
Cancer medicine, 19/01/2020, p. 1-12

Document en ligne

Thème : Médecine. Cote : eD03.05

CHIMIOTHERAPIE ; CANCER OTO RHINO LARYNGOLOGIQUE ; THERAPEUTIQUE ANTI CANCEREUSE ; CHINE

Background: Platinum-based chemotherapy is the standard of care as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC); however, the prognosis of patients with RM-NPC remains poor. The aim of this study was to evaluate the role of anti-epidermal growth factor receptor (anti-EGFR) antibody plus chemotherapy for RM-NPC.
Methods: RM-NPC patients who received first-line chemotherapy plus an anti-EGFR antibody were recruited from Sun Yat-Sen University Cancer Center between July 2007 and November 2017. Survival analyses were performed using the Kaplan-Meier method with a log-rank test. A Cox proportional hazards model was used for the multivariate analyses.
Results: A total of 203 patients were enrolled in the present study. The median follow-up time was 34.3 months (interquartile range: 19.7-66.5 months). The median progression-free survival (PFS) was 8.9 months (95% CI: 7.7-10.0 months) and the median overall survival (OS) was 29.1 months (95% CI: 23.5-34.6 months). The 1-, 3-, and 5-year PFS and OS rates were 35.5% and 79.6%, 15.2% and 42.5%, and 11.6% and 23.6%, respectively. The objective response rate (ORR) was 67.5% and the disease control rate (DCR) was 91.1%. The multivariate analysis identified the following prognostic factors for PFS: anti-EGFR agent (P = .010), recurrence/metastasis sequence (P = .016), KPS (P = .017), and combined chemotherapy regimen (P = .015). Independent risk factors for OS included age >43 years (P = .002), Karnofsky performance score =80 (P < .001), and higher level of baseline Epstein-Barr virus (EBV) DNA (P = .008). Leukopenia was the most common adverse event (AE) in this cohort (any grade, 84.2%; grades 3-4, 43.4%).
Conclusions: Anti-EGFR antibody plus chemotherapy achieved promising antitumor activity with a tolerable toxicity profile in RM-NPC. Thus, randomized clinical trials are warranted to compare the efficacy of chemotherapy with or without anti-EGFR antibody in these patients.

Origine : PubMed

(1) 2 3 4 ... 10 > »

Actions

##titre_notice##